WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being ...

Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) ...

A busy Monday brings louder calls for PBM reform, plus a report on U.S. biotech economic output and jobs, news on avian flu and plant biotech regulations, and more. (834 words, 4 minutes, 10 seconds) ...

Scott Carmer is the former CEO at NexImmune – a Johns Hopkins incubated spin-out which was based on innovative science developed in the lab of co-founder, Jonathan Schneck. During an eight-year career ...

This is the only conference focused specifically on intellectual property in biotechnology, featuring the latest insights from biotech IP experts, as well as networking events designed to promote ...

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors. The Full BIO Board of Directors is comprised of all ...

A collaborative initiative to advance corporate board diversity through partnerships and more.

Apply today to join an unparelled network of BIO Members and to benefit from a number of resources and event discounts. BIO membership is available only to bona fide organizations that promote ...

Here are a few highlights from the policymakers and regulators who spoke at the event. We look forward to seeing you next year!

BIO Business Solutions ® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual ...

Explore how we drive biotechnology innovation. Advancing newer and better medicines, therapeutics, and vaccines is a collective effort that involves an entire ecosystem, not just one person or company ...

"BIO is a crucial trade group representing all biotech and biopharma companies with influence on policies affecting our business and patients with rare diseases in the U.S. Through our participation ...